Pharmafile Logo
  • - PMLiVE
  • - PMLiVE
  • Diversity, Equity and Inclusion
  • Communiqué 53 Cover Image

    • Digital Therapeutics Landscape in Europe

    September 3, 2020 |  

    OPEN Health introduce an overview of regulatory and HTA developments for digital therapeutics in Europe focusing on Germany and the UK

    Digital Therapeutics Landscape in Europe: The Case of Germany and the UK

    The COVID-19 virus crisis has opened immense windows of opportunity in healthcare around the globe. One of the greatest opportunities is in digital health, and in particular, digital therapeutics (DTx). The need for continued medical care combined with social distancing has led to a spike in use of digital health tools worldwide.1 As the interest in and use of digital health has grown during this period, we anticipate that investments in digital health tools will continue to accelerate after the COVID-19 pandemic. When the COVID-19 outbreak started, millions of Chinese people turned to online doctors and online health tools1 to find the needed support for their health. While these developments could create new risks for privacy and data protection, they also represent an unprecedented opportunity to integrate industry 4.0 in healthcare for the benefit of patients.

    HIGHLIGHTS INCLUDE:
    • Opportunities and threats of digital therapeutics after COVID-19
    • Digital therapeutics landscape in the European Union
    • Review and comparison of the German and UK therapeutics landscape
    • Develop game-changing insights and competitive advantage on both a global and local scalepi

    Pink divider

    Download the white paper and learn how it’s happening now!

    Download the Paper- PMLiVE

    1. https://www.cnbc.com/2020/03/26/investments-in-digital-health-care-could-accelerate-after-coronavirus-credit-suisse-says.html

    This content was provided by OPEN Health

    Company Details

    OPEN Health

    OPEN Health

    Email
    Website

     Latest Content from  OPEN Health 

    The right measurement frameworks matter for demonstrating treatment efficacy in clinical trials for Alzheimer’s Disease

    The right measurement frameworks matter for demonstrating treatment efficacy in clinical trials for Alzheimer’s Disease

    OPEN Health Presenting Innovative Research on Capitalizing Data for Patient Access at ISPOR Europe

    OPEN Health Presenting Innovative Research on Capitalizing Data for Patient Access at ISPOR Europe

    Dom Marchant, Chief Creative Officer, joins the executive leadership team at OPEN Health with a new vision to drive the creative communications practice

    Dom Marchant, Chief Creative Officer, joins the executive leadership team at OPEN Health with a new vision to drive the creative communications practice

    Embracing the Patient Voice Within Publications

    This whitepaper will explore multidisciplinary perspectives on how we can better engage patient communities in publications to optimize the value of their contributions, while navigating any uncertainties and reluctance from...

    Navigating the nocebo effect through patient engagement is the key to setting patients up for success

    If you're interested in delving deeper into this topic and understanding how patient engagement can effectively navigate the nocebo effect, we invite you to explore our latest whitepaper.

    OPEN Health announces a new team of experts will lead its HEOR & Market Access Scientific Office

    OPEN Health, a global provider of consultancy, HEOR and market access, and scientific communications services, announced a new team of experts will lead its HEOR & Market Access Scientific Office.

    OPEN Health Appoints Richard Jones as President for Evidence & Access

    OPEN Health is pleased to announce the appointment of Richard Jones as President for Evidence & Access.

    Drive, Discover, Dive_OPEN Health

    Learn how to unlock the power of simplicity in complex omnichannel healthcare communications.

    Novel Oncology Therapies Require Innovative Methods in Oncology Modeling

    Innovative methods in oncology modeling are needed to demonstrate the value of many new cancer treatments, including immuno-oncologic therapies.

    The CM Group rebrands to OPEN Health

    Following its acquisition by OPEN Health in 2022, The CM Group, a US healthcare agency offering a suite of solutions to the biotech and pharma industry, has undergone extensive rebranding...